Basilea Pharmaceutica AG BASILEA .../ CH0011432447 /
| 4/26/2024 3:43:46 PM | Chg. - | Volume | Bid4/26/2024 | Ask4/26/2024 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 40.2500CHF | - | 3,175 Turnover: 281.7500 |
-Bid Size: - | -Ask Size: - | 522.68 mill.CHF | - | 45.86 |
GlobeNewswire
7:15 AM
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
GlobeNewswire
4/24
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
GlobeNewswire
4/9
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GlobeNewswire
4/4
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicati...
GlobeNewswire
3/11
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers mile...
GlobeNewswire
2/13
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...
GlobeNewswire
1/19
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
GlobeNewswire
12/11/2023
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...
GlobeNewswire
11/20/2023
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers thir...
GlobeNewswire
11/13/2023
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
GlobeNewswire
10/31/2023
Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage...
GlobeNewswire
10/19/2023
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold i...
GlobeNewswire
10/17/2023
Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
GlobeNewswire
10/2/2023
Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
GlobeNewswire
9/28/2023
Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for th...
GlobeNewswire
3/8/2022
Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at...
GlobeNewswire
2/15/2022
Basilea to become a leading anti-infectives company backed by strong financial results 2021
GlobeNewswire
1/24/2022
Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications fr...
GlobeNewswire
1/13/2022
Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in Chi...
GlobeNewswire
1/11/2022
Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobipr...
GlobeNewswire
1/10/2022
Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-position
